A fixed-dose combination (FDC) product designed for the comprehensive management of functional gastrointestinal disorders (FGIDs) like Irritable Bowel Syndrome (IBS) and functional dyspepsia, particularly when associated with significant anxiety. It combines an anticholinergic/antispasmodic (Clidinium & Dicyclomine), an anxiolytic (Chlordiazepoxide), and an H2-receptor antagonist (Ranitidine). This combination aims to address the 'brain-gut axis' dysfunction by reducing visceral hypersensitivity, decreasing smooth muscle spasm, suppressing gastric acid, and alleviating anxiety. Its use is controversial and strictly regulated in India due to the presence of a benzodiazepine (chlordiazepoxide).
Adult: One tablet two to three times daily, preferably before meals. The lowest effective dose for the shortest duration (typically not exceeding 2-3 weeks) should be used.
Note: Take orally with a glass of water. Can be taken before meals to prevent meal-induced symptoms. Do not crush or chew. Avoid concomitant antacids within 1-2 hours as they may reduce Ranitidine absorption. Avoid alcohol completely.
The combination exerts a multi-modal action. Clidinium and Dicyclomine competitively inhibit acetylcholine at muscarinic receptors in GI smooth muscle, reducing spasms, motility, and secretions. Chlordiazepoxide potentiates GABAergic inhibition in the CNS (limbic system, reticular formation), producing anxiolytic, sedative, and muscle relaxant effects, indirectly modulating the brain-gut axis. Ranitidine competitively inhibits histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Pregnancy: CONTRANDICATED, especially in first trimester. Chlordiazepoxide is FDA Pregnancy Category D (positive evidence of human fetal risk). Risk of congenital malformations (cleft lip/palate), floppy infant syndrome, withdrawal symptoms in neonate. Ranitidine is Category B but combination is not safe.
Driving: STRONGLY DISCOURAGED. Causes drowsiness, dizziness, blurred vision, and impaired coordination. Patients should not drive or operate machinery until individual response is known, which may take days to weeks.
| Alcohol, Opioids, Barbiturates, other CNS Depressants | Profound additive CNS and respiratory depression, sedation, risk of death. | Major |
| Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Markedly increased chlordiazepoxide levels, leading to excessive sedation and respiratory depression. | Major |
| Other Anticholinergics (Tricyclic Antidepressants, Antipsychotics, Antihistamines) | Additive anticholinergic toxicity: severe dry mouth, urinary retention, ileus, hyperthermia, confusion. | Major |
| Warfarin | Ranitidine may alter warfarin metabolism; monitor INR closely. | Moderate |
| Midazolam, Triazolam | Increased benzodiazepine levels and effects (CYP3A4 substrate). | Major |
| Levodopa | Anticholinergics may reduce gastric motility and absorption of levodopa, decreasing efficacy. | Moderate |
| Digoxin | Anticholinergics may increase digoxin absorption by reducing gut motility, risk of toxicity. | Moderate |
| Metoprolol, Propranolol | Ranitidine may increase bioavailability of some beta-blockers. | Moderate |
| Phenytoin | Ranitidine may inhibit metabolism, increasing phenytoin levels. | Moderate |
| Theophylline | Ranitidine may slightly increase theophylline levels. | Minor |
Same composition (Clidinium (2.5mg) + Chlordiazepoxide (5mg) + Dicyclomine (10mg) + Ranitidine (150mg)), different brands: